Tetragenetics

company

About

Tetragenetics helps people seeking a cost-effective alternative platform technology for the production of genetically engineered proteins.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.54M
Industries
Biopharma,Biotechnology,Therapeutics
Founded date
Jan 1, 2004
Number Of Employee
11 - 50
Operating Status
Active

Tetragenetics is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. Their technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1.54M
Tetragenetics has raised a total of $1.54M in funding over 2 rounds. Their latest funding was raised on Jan 14, 2016 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 14, 2016 Grant $1.54M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Tetragenetics is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Grant